SC 13D 1 tm2421488d1_sc13d.htm SC 13D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

SILK ROAD MEDICAL, INC.

(Name of Issuer)

Common Stock, par value $.001

(Title of Class of Securities)

82710M100

(CUSIP Number of Class of Securities)

David J. Snyderman

Magnetar Capital LLC

1603 Orrington Ave.

Evanston, Illinois 60201

(847) 905-4400

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

August 5, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 82710M100

SCHEDULE 13D

Page 2 of 11

1.	NAME OF REPORTING PERSON: Magnetar Financial LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH REPORTING PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

2,038,076

SOLE DISPOSITIVE POWER

10.

SHARED DISPOSITIVE POWER

2,038,076

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,038,076
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11) 5.01%
14.	TYPE OF REPORTING PERSON IA; OO

CUSIP No. 82710M100

SCHEDULE 13D

Page 3 of 11

1.	NAME OF REPORTING PERSON: Magnetar Capital Partners LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH REPORTING PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

2,038,076

SOLE DISPOSITIVE POWER

10.

SHARED DISPOSITIVE POWER

2,038,076

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,038,076
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11) 5.01%
14.	TYPE OF REPORTING PERSON HC; OO

CUSIP No. 82710M100

SCHEDULE 13D

Page 4 of 11

1.	NAME OF REPORTING PERSON: Supernova Management LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH REPORTING PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

2,038,076

SOLE DISPOSITIVE POWER

10.

SHARED DISPOSITIVE POWER

2,038,076

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,038,076
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11) 5.01%
14.	TYPE OF REPORTING PERSON HC; OO

CUSIP No. 82710M100

SCHEDULE 13D

Page 5 of 11

1.	NAME OF REPORTING PERSON: David J. Snyderman
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America

NUMBER OF
SHARES

BENEFICIALLY
OWNED BY

EACH REPORTING PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

2,038,076

SOLE DISPOSITIVE POWER

10.

SHARED DISPOSITIVE POWER

2,038,076

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,038,076
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11) 5.01%
14.	TYPE OF REPORTING PERSON HC; IN

SCHEDULE 13D

item 1.

security and issuer

This Schedule 13D (this “Statement”) relates to the Common Stock, $0.001 par value (the “Shares”), of Silk Road Medical, Inc., a company incorporated in Delaware (the “Company”). The principal executive office of the Company is 1213 Innsbruck Drive, Sunnyvale, California 94089.

Item 2.

identity and background

(a)            The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and David J. Snyderman (“Mr. Snyderman”) (collectively, the “Reporting Persons”).

This Statement relates to Shares held for the accounts of each of (i) Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), (iii) Magnetar Relative Value Master Fund Ltd, a Cayman Islands exempted company, (“Relative Value Master Fund”), and one Managed Account for the clients of Magnetar Asset Management LLC (“the Managed Account”), collectively (the “Funds”).

Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Snyderman.

(b)            The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13^th Floor, Evanston, Illinois 60201.

(c)            Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Snyderman is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

(d)            None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)            None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)            Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Snyderman is a citizen of the United States of America.

Item 3.

source and amount of funds or other consideration

The aggregate amount of funds used by the Reporting Persons in purchasing the Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $54,755,818.09 (excluding commissions and other execution-related costs).

ITEM 4.

PURPOSE OF TRANSACTION

The Reporting Persons acquired the Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER

The Company reported in their Form 10-Q filed on August 7, 2024 that 40,632,143 Shares were outstanding as of July 31, 2024.

(a)            As of the close of business August 9, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of Shares, which consisted of (i) 1,431,513 Shares held for the benefit of PRA Master Fund and (ii) 449,483 Shares held for the benefit of Systematic Master Fund, (iii) 90,122 Shares held for the benefit of Relative Value Master Fund, and (iv) 66,958 Shares held for the benefit of the Managed Account, and all such Shares represented beneficial ownership of approximately 5.01% of the Shares.

(b)            As of the close of business August 9, 2024, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of Shares, which consisted of (i) 1,431,513 Shares held for the benefit of PRA Master Fund, (ii) 449,483 Shares held for the benefit of Systematic Master Fund, (iii) 90,122 Shares held for the benefit of Relative Value Master Fund, and (iv) 66,958 Shares held for the benefit of the Managed Account, and all such Shares represented beneficial ownership of approximately 5.01% of the Shares.

(c)            Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NASDAQ and various other trading markets.

As disclosed by the Company in the 8-K filed with the SEC on June 18, 2024:

Merger Agreement

On June 17, 2024, Silk Road Medical, Inc. (“Silk Road”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Boston Scientific Corporation, a Delaware corporation (“Boston Scientific”), and Seminole Merger Sub, Inc., a Delaware corporation (“Merger Sub”). The Merger Agreement provides that, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub will merge with and into Silk Road (the “Merger”), with Silk Road continuing as the surviving corporation of the Merger and a wholly-owned subsidiary of Boston Scientific.

In connection with the entry into the Merger Agreement, Silk Road’s board of directors (the “Board”) unanimously determined that the Merger Agreement and the Merger are in the best interests of Silk Road and its stockholders, approved the Merger Agreement and the Merger and recommended that Silk Road’s stockholders adopt the Merger Agreement.

Equity Treatment in the Merger

Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of Silk Road’s common stock (the “Common Stock”) outstanding immediately prior to the Effective Time (subject to certain customary exceptions specified in the Merger Agreement) will be cancelled and converted automatically into the right to receive $27.50 in cash, without interest (the “Merger Consideration”) and subject to applicable taxes.

(d)            No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

Item 6.

contracts, arrangements, understandings or relationships with respect to the securities of the issuer

Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

A client of Magnetar Financial has entered into a total return swap agreement giving it economic exposure to the Company.

Magnetar Asset Management LLC (“Magnetar Asset Management”) is an SEC registered investment adviser and an affiliate of Magnetar Financial. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Asset Management. Certain clients of Magnetar Asset Management have entered into total return swap agreements giving them economic exposure to the Company.

Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 12, 2024

	magnetar financial llc

	By: Magnetar Capital Partners LP, its Sole Member
	By: Supernova Management LLC, its General Partner

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

	magnetar capital partners LP

	By: Supernova Management LLC, its General Partner

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC

	supernova management llc

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman, Manager

	DAVID J. SNYDERMAN

	By:	/s/ Hayley Stein
	Name:	Hayley Stein
	Title:	Attorney-in-fact for David J. Snyderman

SCHEDULE A

Funds

Date	Number of Shares Bought	Price Per Share($) ⁽¹⁾⁽²⁾
6/18/2024	787,826	26.85254 ⁽³⁾
6/20/2024	249,455	26.87559⁽⁴⁾
6/21/2024	182,814	26.89737⁽⁵⁾
6/24/2024	148,779	26.88864⁽⁶⁾
6/25/2024	37,906	26.89984⁽⁷⁾
6/26/2024	325,669	26.84312⁽⁸⁾
6/27/2024	200,892	26.84476⁽⁹⁾
6/282024	37,032	26.89493⁽¹⁰⁾
7/1/2024	745	26.90000
8/1/2024	540	27.03000
8/2/2024	27,248	27.02392^.(11)
8/5/2024	39,170	26.99169⁽¹²⁾

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $26.85254 per share, at prices ranging from $26.8 to $26.9 per share.

(4) Reflects a weighted average purchase price of $26.87559 per share, at prices ranging from $26.815 to $26.9 per share.

(5) Reflects a weighted average purchase price of $26.89737 per share, at prices ranging from $26.88 to $26.9 per share.

(6) Reflects a weighted average purchase price of $26.88864 per share, at prices ranging from $26.85 to $26.9 per share.

(7) Reflects a weighted average purchase price of $26.89984 per share, at prices ranging from $26.895 to $26.9 per share.

(8) Reflects a weighted average purchase price of $26.84312 per share, at prices ranging from $26.8 to $26.9 per share.

(9) Reflects a weighted average purchase price of $26.84476 per share, at prices ranging from $26.79 to $26.90 per share.

(10) Reflects a weighted average purchase price of $26.89493 per share, at prices ranging from $26.88 to $26.9 per share.

(11) Reflects a weighted average purchase price of $27.02392 per share, at prices ranging from $27 to $27.03 per share.

(12) Reflects a weighted average purchase price of $26.99169 per share, at prices ranging from $26.9 to $27.03 per share.

EXHIBIT INDEX

Exhibit No.		Description

99.1		Joint Filing Agreement, dated as of August 12, 2024, among the Reporting Persons.
99.2		Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on August 12, 2024.

SEC Form SC 13D filed by Silk Road Medical Inc.